Piyush Jain
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Piyush Jain has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Alexandre Denadai-Souza
Laboratory of Mucosal Biology, Hepatology Research Unit, Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium
1 shared publication Anisha Prabhakar
West Hertfordshire Hospitals NHS Trust, Hertfordshire, UK
1 shared publicationAnne Griguer
West Hertfordshire Hospitals NHS Trust, Hertfordshire, UK
1 shared publicationBart N. Lambrecht
Laboratory of Immunoregulation, VIB Center for Inflammation Research, Ghent, Belgium
1 shared publicationChristine Breynaert
Allergy and Clinical Immunology Research Group, KU Leuven Department of Microbiology, Immunology and Transplantation, Leuven, Belgium
1 shared publicationCintya Lopez-Lopez
Gastrointestinal Diseases Research Unit, Queen’s University, Kingston, Canada
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 13 January 2021
- Published by Springer Nature in Nature
- Vol. 590 (7844) , 151-156
Local immune response to food antigens drives meal-induced abdominal pain
Up to 20% of people worldwide develop gastrointestinal symptoms following a meal1, leading to decreased quality of life, substantial morbidity and high medical costs. Although the interest of both the scientific and lay communities in this issue has increased markedly in recent years, with the worldwide introduction of gluten-free and other diets, the underlying mechanisms of food-induced abdominal complaints remain largely unknown. Here we show that a bacterial infection and bacterial toxins can trigger an immune response that leads to the production of dietary-antigen-specific IgE antibodies in mice, which are limited to the intestine. Following subsequent oral ingestion of the respective dietary antigen, an IgE- and mast-cell-dependent mechanism induced increased visceral pain. This aberrant pain signalling resulted from histamine receptor H1-mediated sensitization of visceral afferents. Moreover, injection of food antigens (gluten, wheat, soy and milk) into the rectosigmoid mucosa of patients with irritable bowel syndrome induced local oedema and mast cell activation. Our results identify and characterize a peripheral mechanism that underlies food-induced abdominal pain, thereby creating new possibilities for the treatment of irritable bowel syndrome and related abdominal pain disorders.
- 13 January 2021
- Published by Springer Nature in Nature
- Vol. 590 (7844) , 151-156
Top Cited PapersOpen AccessLocal immune response to food antigens drives meal-induced abdominal pain
Up to 20% of people worldwide develop gastrointestinal symptoms following a meal1, leading to decreased quality of life, substantial morbidity and high medical costs. Although the interest of both the scientific and lay communities in this issue has increased markedly in recent years, with the worldwide introduction of gluten-free and other diets, the underlying mechanisms of food-induced abdominal complaints remain largely unknown. Here we show that a bacterial infection and bacterial toxins can trigger an immune response that leads to the production of dietary-antigen-specific IgE antibodies in mice, which are limited to the intestine. Following subsequent oral ingestion of the respective dietary antigen, an IgE- and mast-cell-dependent mechanism induced increased visceral pain. This aberrant pain signalling resulted from histamine receptor H1-mediated sensitization of visceral afferents. Moreover, injection of food antigens (gluten, wheat, soy and milk) into the rectosigmoid mucosa of patients with irritable bowel syndrome induced local oedema and mast cell activation. Our results identify and characterize a peripheral mechanism that underlies food-induced abdominal pain, thereby creating new possibilities for the treatment of irritable bowel syndrome and related abdominal pain disorders.
- Open Access
P02 Efficacy of intravenous metoprolol for heart rate control in patients undergoing CT coronary angiography
Introduction Computer tomography coronary angiography (CTCA) can be performed with improved image quality and at lower radiation dose when heart rate is lowered to less than 60 beats per minute (bpm). In our centre intravenous Metoprolol is administered on the CT table targeting a heart rate below 60 bpm. The aim of this audit was to assess the efficacy of intravenous beta-blockade to achieve optimal heart rates in patients undergoing CTCA. Methods We carried out a retrospective case note review of all patients undergoing CTCA between 1 – 30 November 2018. Scanning was performed using a 320-detector row scanner with prospective gating (Toshiba Aquilon One). Data collected included attending radiologist/cardiologist, dose of Metoprolol, heart rate at time of image acquisition and baseline patient characteristics. Results Case notes of 131 consecutive patients referred for CTCA were reviewed. The mean heart rate achieved was 61.7 bpm (range 30–130 bpm). The average administered dose of metoprolol was 15.5 mg (range 0–60 mg). 51% of patients achieved a heart rate less than 60 bpm at the time of scanning. For patients achieving target heart rates below 60 bpm the average dose of metoprolol was 9.3 mg, and 22.4 mg for those with heart rates greater than 60 bpm at the time of image acquisition. Conclusion Routine administration of intravenous beta-blocker peri-procedure fails to achieve optimal heart rate control in approximately half of all patients undergoing CTCA. Alternative protocols including pre-treatment with a short course of oral beta-blockers should be considered.
Open AccessP02 Efficacy of intravenous metoprolol for heart rate control in patients undergoing CT coronary angiography
Introduction Computer tomography coronary angiography (CTCA) can be performed with improved image quality and at lower radiation dose when heart rate is lowered to less than 60 beats per minute (bpm). In our centre intravenous Metoprolol is administered on the CT table targeting a heart rate below 60 bpm. The aim of this audit was to assess the efficacy of intravenous beta-blockade to achieve optimal heart rates in patients undergoing CTCA. Methods We carried out a retrospective case note review of all patients undergoing CTCA between 1 – 30 November 2018. Scanning was performed using a 320-detector row scanner with prospective gating (Toshiba Aquilon One). Data collected included attending radiologist/cardiologist, dose of Metoprolol, heart rate at time of image acquisition and baseline patient characteristics. Results Case notes of 131 consecutive patients referred for CTCA were reviewed. The mean heart rate achieved was 61.7 bpm (range 30–130 bpm). The average administered dose of metoprolol was 15.5 mg (range 0–60 mg). 51% of patients achieved a heart rate less than 60 bpm at the time of scanning. For patients achieving target heart rates below 60 bpm the average dose of metoprolol was 9.3 mg, and 22.4 mg for those with heart rates greater than 60 bpm at the time of image acquisition. Conclusion Routine administration of intravenous beta-blocker peri-procedure fails to achieve optimal heart rate control in approximately half of all patients undergoing CTCA. Alternative protocols including pre-treatment with a short course of oral beta-blockers should be considered.